You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage IV urethral cancer

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Trial in Shanghai (CS1001 mAb, CS1001 )

Active, not recruiting
  • Non Small Cell Lung Cancer
  • CS1001 monoclonal antibody
  • CS1001 placebo
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Nov 8, 2022

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Study of Screening Brain MRIs in Stage IV Breast Cancer

Recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Magnetic Resonance Imaging
  • Tampa, Florida
    Moffitt Cancer Center
Sep 30, 2022

Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

Not yet recruiting
  • Stage IIIB(N2) Non-small Cell Lung Cancer
  • +3 more
  • Pembrolizumab 200 mg IV infusion
  • Beijing, Beijing, China
    Peking University
May 30, 2023

Defining Clinical Potential of Mass Response asBiomarker for

Recruiting
  • Stage III Breast Cancer
  • +5 more
    • Columbus, Georgia
      Columbus Regional Research Institute, John B. Amos Cancer Center
    Jul 13, 2022

    Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 Trial in Rochester (MRI-Guided

    Not yet recruiting
    • Prostate Carcinoma
    • +2 more
    • MRI-Guided Transurethral Ultrasound Ablation
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jun 28, 2022

    Recurrent NSCLC, Stage IIIA NSCLC, Stage IIIB NSCLC Trial in Buffalo (therapeutic lymphadenectomy (TEMLA) and Stereotactic Body

    Completed
    • Recurrent Non-small Cell Lung Cancer
    • +3 more
    • therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
    • quality-of-life assessment
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jul 20, 2022

    Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago

    Recruiting
    • Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
    • +2 more
    • Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
    • Chicago, Illinois
      Northwestern University
    Nov 16, 2022

    Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Atlanta (Aldesleukin,

    Not yet recruiting
    • Lung Non-Small Cell Carcinoma
    • +3 more
    • Aldesleukin
    • Pembrolizumab
    • Atlanta, Georgia
      Emory University/Winship Cancer Institute
    Aug 8, 2022

    China With Non-Small-Cell Lung Cancer That is Unable to be

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
      • (no location specified)
      May 16, 2023

      NSCLC Metastatic Trial in Chengdu (Camrelizumab, stereotactic body radiation therapy, Chemotherapy)

      Recruiting
      • Non-small Cell Lung Cancer Metastatic
      • Chengdu, Sichuan, China
        Sichuan Cancer Hospital & Institute
      Jul 21, 2022

      Lung Cancer, NSCLC Trial in Tampa (Vorinostat, Pembrolizumab)

      Active, not recruiting
      • Lung Cancer
      • Non-small Cell Lung Cancer
      • Tampa, Florida
        H. Lee Moffitt Cancer Center and Research Institute
      Nov 10, 2022

      Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

      Not yet recruiting
      • Recurrent Lung Non-Small Cell Carcinoma
      • Stage IV Lung Cancer AJCC v8
      • Biospecimen Collection
      • +5 more
      • (no location specified)
      Sep 7, 2023

      Advanced Kidney Cancer Trial in Tianjin (Tislelizumab Lenvatinib)

      Recruiting
      • Advanced Kidney Cancer
      • Tislelizumab Lenvatinib
      • Tianjin, Tianjin, China
        Changyi Quan
      Aug 4, 2022

      Postoperative Circulating Tumor DNA Monitoring for Colorectal

      Active, not recruiting
      • Colorectal Cancer
      • Serial ctDNA monitoring
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Nov 28, 2023

      Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative Trial in United States (Atezolizumab, Carboplatin,

      Active, not recruiting
      • Triple Negative Breast Cancer
      • +3 more
      • Washington, District of Columbia
      • +5 more
      Dec 1, 2022

      Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)

      Terminated
      • Estrogen Receptor Positive
      • +16 more
      • Biopsy of Breast
      • +5 more
      • Los Angeles, California
        UCLA / Jonsson Comprehensive Cancer Center
      Sep 22, 2022

      Unresectable Stage IIIB-IV Malignant Melanoma Trial in Japan (Talimogene laherparepvec)

      Completed
      Has Results
      • Unresectable Stage IIIB-IV Malignant Melanoma
      • Talimogene laherparepvec
      • Nagoya-shi, Aichi, Japan
      • +8 more
      Jan 13, 2023

      Gastric Cancer, Adjuvant Chemo, XO Trial in Seoul (Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin)

      Recruiting
      • Gastric Cancer, Adjuvant Chemotherapy, XO
      • Docetaxel and capecitabine and oxaliplatin
      • capecitabine and oxaliplatin
      • Seoul, Korea, Republic of
        Asan Medical Center
      Dec 30, 2022

      Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

      Active, not recruiting
      • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
      • +11 more
      • Washington, District of Columbia
      • +6 more
      Feb 2, 2023

      Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma Trial in Portland (Wee1

      Not yet recruiting
      • Advanced Fallopian Tube Carcinoma
      • +10 more
      • Wee1 Inhibitor ZN-c3
      • Portland, Oregon
        OHSU Knight Cancer Institute
      Jan 25, 2023

      Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

      Active, not recruiting
      • Edema
      • +8 more
      • Laboratory Biomarker Analysis
      • Pembrolizumab
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 23, 2023

      Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

      Recruiting
      • Fallopian Tube Endometrioid Adenocarcinoma
      • +17 more
      • Biopsy
      • +3 more
      • Augusta, Georgia
      • +4 more
      Jan 25, 2023

      Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 Trial (drug, procedure,

      Not yet recruiting
      • Advanced Lung Non-Small Cell Carcinoma
      • +3 more
      • (no location specified)
      Oct 21, 2023

      Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological

      Completed
      • Stage IIIB Non-Small Cell Lung Cancer AJCC v7
      • Stage IV Non-Small Cell Lung Cancer AJCC v7
      • Laboratory Biomarker Analysis
      • +3 more
      • Portland, Oregon
        OHSU Knight Cancer Institute
      Sep 14, 2022